Floatz logo
Floatz Rating
BB67/100
Confidence
Indicative
v0.2
Sponsor
Sichuan Baili Pharmaceutical Co., Ltd.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07545460CT.gov
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
—Not Yet Recruiting———
NCT07218809CT.gov
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
—Recruiting———
NCT06994195CT.gov
A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)
—Recruiting———
NCT05870748CT.gov
REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
—Terminated———
NCT05295589CT.gov
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
—Withdrawn———
NCT04739800CT.gov
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
—Active Not Recruiting———
NCT04209855CT.gov
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression
—Completed———
NCT02822157CT.gov
Circulating Tumor DNA Guiding (Olaparib) Lynparza® Treatment in Ovarian Cancer
—Unknown———
NCT02502266CT.gov
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
—Active Not Recruiting———
NCT02631876CT.gov
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
—Completed———
Show 8 more trials
NCT02584478CT.gov
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
—Unknown———
NCT02569957CT.gov
Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
—Terminated———
NCT02312245CT.gov
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
—Completed———
NCT02419495CT.gov
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
—Terminated———
NCT02364713CT.gov
MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer
—Terminated———
NCT02107378CT.gov
Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma
—Terminated———
NCT01840943CT.gov
A Study to Compare CAELYX With Topotecan HCL in Patients With Recurrent Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy
—Terminated———
NCT01012817CT.gov
Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer
—Active Not Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Ovarian Carcinoma

AssetSponsorPhaseRating
Nogitecan (this asset)Sichuan Baili Pharmaceutical Co., Ltd.P3BB · 67
Mirvetuximab SoravtansineAstraZenecaP3BBB
TrabectedinAGO Research GmbHP4BBB
CarboplatinUniversity of WashingtonP3BB
IrinotecanOHSU Knight Cancer InstituteP2BB
OlaparibImunonP4BB
DurvalumabAGO Research GmbHP2BB
LenvatinibUniversity Medical Center GroningenP4BB
PalbociclibUniversity Medical Center GroningenP4BB

+42 more in the Ovarian Carcinoma cohort

Other indications for Nogitecan

IndicationSponsorPhaseRating
Primary Peritoneal Carcinoma—P3BBB · 74
Cancer Of Unknown Primary Site—P2BBB · 72
Non-Small Cell Lung Carcinoma—P3BBB · 72

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Nogitecan in Ovarian Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nogitecan-ovarian-carcinoma-23067

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →